Compare Abadi Lestari Indonesia Tbk. (RLCO) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abadi Lestari Indonesia Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Abadi Lestari Indonesia Tbk. trades at Rp4,500 (market cap 14.25T, 449.7K 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Abadi Lestari Indonesia Tbk. is far larger — about 136.5× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| RLCO | SCPI | |
|---|---|---|
Market Cap | 14.25T | 104.4B |
Volume | 449.7K | — |
Lot | 4.5K | — |
Turnover | 2B | — |
Average Price | 4,442.22 | — |
Value | 2B | — |
Indicative Equilibrium Price | 4,500 | — |
Indicative Equilibrium Volume | 23 | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abadi Lestari Indonesia Tbk.
PT Abadi Lestari Indonesia (the Entity) was established based on Notarial Deed No. 166 of Siti Nurul Hidajah, S.H., M.Kn., Notary in Bojonegoro, dated August 11, 2014. The Entity started its commercial operations in 2014. PT Abadi Lestari Indonesia is the parent entity, whereas Edwin Pranata is the ultimate beneficial owner of the group.
Read more on RLCO →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
